tbuckley/cabot-search huggingface dataset:
Climate Change and Health
Authors: Daniel S. Berman
Journal: Annals of Internal Medicine (2016)

Letters15 November 2016Climate Change and HealthDaniel S. Berman, MDDaniel S. Berman, MDFrom Montefiore Medical Center, Bronx, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0412 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a position paper on climate and health, Crowley recommends that physicians “advocate for climate change adaptation and mitigation policies” (1). As an internist and infectious disease specialist, I find this recommendation difficult to follow. Such advocacy might also compromise my ability to influence patients in other areas of health care.As a physician, it is my responsibility to analyze data provided in the medical literature and not just blindly accept conclusions that are stated even by prestigious medical societies. My education and training allow me to review medical data and come to conclusions about their reliability ...Reference1. Crowley RA; Health and Public Policy Committee of the American College of Physicians. Climate change and health: a position paper of the American College of Physicians. Ann Intern Med. 2016;164:608-10. [PMID: 27089232]. doi:10.7326/M15-2766 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Montefiore Medical Center, Bronx, New York.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0412. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoClimate Change and Health: A Position Paper of the American College of Physicians Ryan A. Crowley and Climate Change and Health Erik Mondrow Climate Change and Health Eric J. Reines Climate Change and Health Ryan A. Crowley , Darilyn V. Moyer , and Douglas M. DeLong Metrics 15 November 2016Volume 165, Issue 10Page: 746KeywordsAntibioticsClimate changeHealth careInfectious diseasesLyme diseaseMedical educationPatient advocacyScience policyStatinsVaccine hesitancy ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study
Authors: Bethany Warren, James S Pankow, Kunihiro Matsushita, Naresh M Punjabi, Natalie R Daya, Morgan Grams, Mark Woodward, Elizabeth Selvin
Journal: The Lancet Diabetes & Endocrinology (2016)
Patterns of ribosomal protein expression specify normal and malignant human cells
Authors: Joao C. Guimaraes, Mihaela Zavolan
Journal: Genome biology (2016)

Ribosomes are highly conserved molecular machines whose core composition has traditionally been regarded as invariant. However, recent studies have reported intriguing differences in the expression of some ribosomal proteins (RPs) across tissues and highly specific effects on the translation of individual mRNAs. To determine whether RPs are more generally linked to cell identity, we analyze the heterogeneity of RP expression in a large set of human tissues, primary cells, and tumors. We find that about a quarter of human RPs exhibit tissue-specific expression and that primary hematopoietic cells display the most complex patterns of RP expression, likely shaped by context-restricted transcriptional regulators. Strikingly, we uncover patterns of dysregulated expression of individual RPs across cancer types that arise through copy number variations and are predictive for disease progression. Our study reveals an unanticipated plasticity of RP expression across normal and malignant human cell types and provides a foundation for future characterization of cellular behaviors that are orchestrated by specific RPs.
Successful Treatment af a Hairy Cell Leukemia (HCL) with Pentostatin in a Cardiac Transplant Recipient.
Authors: Alina Zamfir, Vincent Leymarie, Anne-Cecile Galoisy, Annie Falkenrodt, Eric Epailly, Cecile Fohrer, Lahoucine Mahmal, Raoul Herbrecht
Journal: Blood (2004)
Altered Oxygenation, Vascular and Ischemic Pain Responses in Adults with Sickle Cell Anemia
Authors: Nathan S Fishman, Joseph Kim, Daniel Lichy, Kathleen Vaughan, Stephen Yoon, Niral Sheth, James Ahad, Deepika Darbari, Katherine Chadwick, Hans Ackerman, Alexander M. Gorbach, James G. Taylor
Journal: Blood (2015)
OP0207 Transmembrane TNF-Alpha Reverse Signaling Leading To TGF-Beta Production Is Selectively Activated by Anti-TNF-Alpha Targeting Molecules
Authors: A. Pallai, B. Kiss, G. Vereb, M. Armaka, G. Kollias, Z. Szekanecz, Z. Szondy
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tumor necrosis factor (TNF)-a, a potent pro-inflammatory cytokine, is generated in a precursor form called transmembrane (m)TNF-a that is expressed on the surface TNF-a producing cells. TNF-a was shown to act both as a ligand by binding to TNF-a receptors, as well as a receptor that transmits outside-to-inside (reverse) signals back into the mTNF-a bearing cells. Anti-TNF-a targeting molecules which neutralize TNF-a with the same efficiency show disease specific effectiveness. <h3>Objectives</h3> The aim of the present study was to characterize mTNF-a signaling and to test whether known anti-TNF-a targeting molecules trigger mTNF-a signaling in human macrophages. <h3>Methods</h3> TNF-a expression and localization was studied in mouse bone marrow derived macrophages by RT-QPCR or FACS analysis and confocal microscopy. mTNF-a signaling was triggered by coated anti-TNF-a antibodies and tested by a Phospho-MAPK array. The cytokine induced was determined by RT-QPCR analysis and ELISA. The effect of mTNF-a signaling on lipopolysaccharide (LPS)-induced pro-inflammatory cytokine formation was tested with a cytokine array. <h3>Results</h3> Non-activated macrophages express basal levels of mTNF-a and respond to anti-TNF-a antibodies by triggering the mitogen-activated protein kinase kinase 4 signaling pathway leading transforming growth factor (TGF)-b production. Exposure to LPS further induced the expression of mTNF-a, and mTNF-a signaling suppressed the LPS-induced pro-inflammatory response via TGF-b. Since apoptotic cells downregulate their TNF receptors, they do not trigger mTNF-a for TGF-b production. Etanercept, a soluble TNF-a receptor, does not, while golimumab and infliximab, which are anti-TNF-a antibodies, do trigger TGF-b production in human macrophages. <h3>Conclusions</h3> Induction of TGF-b production by mTNF-a or by receptors triggered by apoptotic cells could be considered in the therapy of inflammatory diseases and may, in part, also account for differences in the actions of various TNF-a inhibitors. <h3>Disclosure of Interest</h3> None declared
AB0172 Usefulness of The Japanese Version of The Patient-Rated Elbow Evaluation in Patients with Rheumatoid Arthritis
Authors: A. Takeshita, D. Kaneda, M. Horita, T. Machida, R. Nakahara, Y. Nasu, K. Hashizume, K. Nishida, T. Ozaki
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patient self-administered questionnaires remove the possibility of observer bias, and are important instruments for the assessment of clinical outcome. The patient-rated elbow evaluation (PREE) is a joint-specific, self-administered questionnaires. <h3>Objectives</h3> We aimed to investigate the correlation between the Japanese version of PREE (PREE-J) and other clinical parameters in rheumatoid arthritis (RA) patients before and after total elbow arthroplasty (TEA). <h3>Methods</h3> Thirty-five elbows in 32 RA patients (M/F: 3/29) were replaced by TEA. The mean age was 62.1 (range 41–79) years at the time of surgery, the mean follow-up period was 21.5 (range 12–36) months. All patients were assessed pre- and post-operatively by PREE-J, elbow and forearm range of motion (ROM), Disease Activity Score with 28 joint using CRP (DAS28-CRP), Mayo Elbow Performance Score (MEPS), Japanese version of the Disabilities of the Arm, Shoulder and HAND (DASH-JSSH) and Health Assessment Questionnaire Disability Index (HAQ-DI). The changes of parameters after surgery were examined by Wilcoxon signed-rank test, and the correlation between PREE-J and other parameters was examined using Spearman9s correlation coefficients. <h3>Results</h3> Both pre- and post-operative PREE-J significantly correlated with DAS28-CRP, DASH-JSSH, and HAQ-DI. Significant improvement was observed after surgery in all parameters except for HAQ-DI. The mean postoperative MEPS improved from 50.3±16.4 points to 98.1±3.2 points, the average postoperative PREE-J improved from 54.7±19.3 points to 27.1±24.4 points. The correlation between PREE-J and MEPS was significant preoperatively (p&lt;0.01), but the correlation disappeared postoperatively. The correlation between PREE-J and ROM was not significant pre- and post-operatively. <h3>Conclusions</h3> The current study indicated that elbow evaluation by patients who underwent TEA showed significant correlation with disease activity, upper limb function and disability in daily life. It was revealed preoperative PREE-J also well correlated with MEPS, which is widely accepted evaluation system by elbow surgeons. Interestingly, PREE-J did not correlate with MEPS and ROM postoperatively. As PREE-J contains many questions about complex motions required the multiple joint function of upper extremity, it is possible PREE-J might be influenced by other joints affected by RA. MEPS (up to 100 points) evaluates pain (45), ROM (20), function (25) and instability (10) of the elbow, and reached almost perfect score by TEA. PREE-J evaluates pain and function with more detailed questionnaires than MEPS, some of them cannot be solved by a single joint surgery. Our results suggested PREE-J might be useful and wide range evaluation instrument for functional improvement of upper extremity after TEA. <h3>Disclosure of Interest</h3> None declared
High Mortality Associated with Neurological Complications after Allogeneic Stem Cell Transplantation
Authors: Sara Lozano, Amaya Zabalza, Intza Aoiz, Mohamed Hamdi Djatri, Pedro Arregui, Ivan Quispe, Mari Cruz Montoya, Montserrat Alvarellos, Patricia Garcia Ramirez, Ana Gorosquieta, Katy Perez Equiza, Eduardo Olavarria
Journal: Blood (2014)
Microporous Biphasic Calcium Phosphate Granules (MBCP®) Retain Immunological Properties of Bone Marrow-Derived Mesenchymal Stromal Cells and Promote Osteoblastic Differentiation
Authors: Giulio Bassi, Luciano Pacelli, Cedric Mènard, Francesco Bifari, Luc Sensebé, Frederic Deschaseaux, Fabien Guilloton, Serge Baroth, Pierre Layrolle, Giovanni Pizzolo, Karin Tarte, Mauro Krampera
Journal: Blood (2011)
Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.
Authors: Dragana Milojkovic, Satyajit Sahu, Jeffery Henderson, Barbara H. Czepulkowski, John R. Salisbury, William T. Bellamy, Stephen Devereux, Antonio Pagliuca, Aloysius Y.L. Ho, Ghulam J. Mufti
Journal: Blood (2004)
Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Nancy M. Hardy, Vicki Fellowes, Jacopo Mariotti, Charles Carter, Carl June4, Bruce L. Levine4, Frances Hakim, Robert Vonderheide4, Ronald Gress, Elizabeth J. Read, Daniel Fowler, Michael R. Bishop
Journal: Blood (2005)
The Clinical Characteristics and Therapeutic Status of Multiple Myeloma in China- a 23 Years Retrospective Analysis in One Single Center.
Authors: Lugui Qiu, Yu-jie Mai, Rei Li, Dehui Zou, Yafei Wang, Yao-zhong Zhao, Renchi Yang, Jianxiang Wang, Zhijian Xiao, Mingzhe Han, Linsheng Qian
Journal: Blood (2004)
Abstract 275: The Effect of High Salt-diet on Pioglitazone Treated-db/db-/- mice
Authors: Patience O Obih, Michael C Ezebuenyi, Akeem P Jimoh, John-Clifford A Obih
Journal: Circulation Research (2015)

The objective of this study was to evaluate the impact of high-salt-diet on pioglitazone treated db/db mice. Groups of 6 weeks-old db/db mice obtained from Jackson Laboratory were given either pioglitazone (0.02%) in diet or pioglitazone (0.02%) plus high salt-diet (8% NaCl) for 6 to 12 weeks. Control groups received either pioglitazone or normal salt diet. During the course of treatment, urine volume, urine sodium, creatinine and blood glucose were measured in the animals. For urine collection, mice were placed in metabolic cages. In order to evaluate whether differences exist between diabetic animals that received pioglitazone or not in the handling of a sodium load and to characterize the transport mechanisms involved, at the end of experimental period the animals were given an acute sodium load (physiological saline), 1.25 ml/100 g body weight by intraperitoneal route. The sodium load was repeated in mice that was treated 15 minutes earlier with hydrochlorothiazide (40 mg/kg i.p.) or furosemide (8 mg/kg i.p.), or amiloride (1.65 mg/kg). The animals were placed in metabolic cages and urine voided was collected over 5 hr. for determination of urine volume and sodium. Sodium was determined by flame photometer. No significant changes were observed in mean arterial blood pressure in all the groups (at p 0.05). There was significant increase in UNav with all the diuretics in db/db mice that received high salt diet at 6 weeks. The blood pressure did not increase with the sodium diet. This might be due to natriuresis resulting from polyurea in the diabetic condition of the mice.
Risk Factors Associated with Occurrence of Febrile Neutropenia in NHL Patients in the First Cycle of Chemotherapy - A Prospective Multivariate Model.
Authors: Ruth Pettengell, Andre Bosly, Thomas D. Szucs, Christian Jackisch, Robert Leonard, Robert Paridaens, Manuel Constenla, Matthias Schwenkglenks
Journal: Blood (2007)
AB0030 Cytokine Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Authors: A. Novikov, E. Aleksandrova, Z. Verizhnikova, T. Panafidina, T. Popkova, D. Karateev, E. Luchihina, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Our aim was to compare serum levels of cytokines in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). <h3>Objectives</h3> Comparative data on cytokine profile in SLE and rheumatoid arthritis RA patients are scarce. <h3>Methods</h3> We examined serum samples from 80 pts with SLE, median and interquartile range (25th–75th percentile) of disease duration 48 (2–432) months; age 31,5 (16–65) years; 72 female; 74 pts with RA, disease duration 90,0 (30,00–192,0) months; age 54,0 (44,0–62,0) years; 59 female, and 28 healthy donors. Cytokine analyses were performed with Bio-Plex® technology (Human Grp I Cytokine 27-plex panel). <h3>Results</h3> Pts with SLE had significantly lower levels of IL-1β, -1ra, -2, -9, eotaxin, G-CSF, IFN-γ, MIP-1β, TNF-α, VEGF and higher levels of IL-4, -6, -8, -12, GM-CSF, MCP-1, PDGF-BB, RANTES than healthy donors. Compared to RA, cytokine/chemokine levels from SLE were significantly different. The concentrations of IL-1β, -1ra, -2, -5, -6, -7, -9, -10, -13, 15, eotaxin, FGF, G-CSF, IFN-γ, IP-10, MIP-1α, TNF-α, VEGF in SLE were significantly lower than RA. The concentrations of IL-4, -8, MCP-1, MIP-1β, PDGF-BB, RANTES was higher in the SLE cohort (Table 1). <h3>Conclusions</h3> Serum concentration of most proinflammatory, Th-2 related, bone marrow–derived cytokines, stromal cells and angiogenic factors in SLE pts is substantially lower than in healthy donors and pts witch RA. These data demonstrate significantly higher chemokine levels in SLE versus RA. <h3>References</h3> Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461–6. Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010; 62(2):383–91. doi: 10.1002/art.27186. Sieber J, Daridon C, Fleischer SJ, Fleischer V, Hiepe F, Alexander T, Heine G, Burmester GR, Fillatreau S, Dörner T. Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. Arthritis Res Ther. 2014;16(6):477. doi: 10.1186/s13075-014-0477-1. <h3>Disclosure of Interest</h3> None declared
BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production
Authors: Mamatha M. Reddy, Anagha Deshpande, Atsushi Nonami, Ellen L. Weisberg, Tirumala K. Chowdary, James D. Griffin, Martin Sattler
Journal: Blood (2012)
Alterations In HLA-DR Expression In Peripheral Blood Mononuclear Cells Are Associated with An Elevated Tricuspid Regurgitant Jet Velocity and Pulmonary Hypertension of Sickle Cell Disease
Authors: Elizabeth Klings, Daniel A Dworkis, Surinder Safaya, Guihua Li, Lynda Reid, Paola Sebastiani, Clinton T. Baldwin, Martin H. Steinberg
Journal: Blood (2010)
CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.
Authors: Shabnam Tangri, Naveen Dakappagari, Annalee Estrellado, Andrew P. Weng, Elizabeth Holmes, M. Wayne Saville, Kandasamy Hariharan, Steffan Ho
Journal: Blood (2009)
SP0162 Becoming A Bookmaker: The Odds of Rheumatoid Arthritis
Authors: D. Van Der Woude
Journal: Annals of the Rheumatic Diseases (2016)

"Doctor, what exactly is my risk of getting rheumatoid arthritis?" Despite all our knowledge about rheumatoid arthritis (RA), this question is often difficult to answer. This presentation will review familial risk in RA and the underlying genetic risk factors, as well as environmental risk factors for disease. Autoantibodies are a potent prognostic marker when it comes to the risk of developing RA, and play a key role in current pathophysiological hypotheses. The latest concepts of how the various risk factors contribute to disease onset will be discussed, along with strategies to easily communicate the concept and extent of RA-risk to our patients. <h3>Disclosure of Interest</h3> None declared
PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia.
Authors: Lars Klemm, Niklas Feldhahn, Thomas K. Hoffmann, Wolf-Karsten Hofmann, Hassan Jumaa, Markus Muschen
Journal: Blood (2007)
Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
Authors: David S Siegel, Sundar Jagannath, Roman Hajek, Meletios A. Dimopoulos, Sung-Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson
Journal: Blood (2010)
Therapeutic approach for primary plasma cell leukemia: case reports and a review of the literature
Authors: Takayuki Tabayashi, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Morihiko Sagawa, Tomoe Nemoto, Reiko Watanabe, Michihide Tokuhira, Shigehisa Mori, Masahiro Kizaki
Journal: Annals of Oncology (2015)
AB1082-HPR Providing Drug Counselling on Methotrexate Is One Occasion Enough?
Authors: S.J. Ryan, C. Thwaites, S. Kamath
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Methotrexate is used in the treatment of patients with an active inflammatory arthritis. Patients routinely receive drug information on the commencement of treatment, often from the rheumatology nurse specialist, and can remain on Methotrexate for many years if it remains safe and effective. Despite the long duration of use of Methotrexate there is often no mechanism to reinforce information about continuing to take the medication safely. <h3>Objectives</h3> The aim of this survey was to establish what safety information patients recalled receiving about Methotrexate and whether patients would like to be updated with information about taking this medication. <h3>Methods</h3> A questionnaire was developed and distributed to patients attending for their Methotrexate drug monitoring appointment in a rheumatology community hospital. The content of the questionnaire focused on: a) The side effects patients had been asked to report. b) When methotrexate could be safely taken (including pregnancy, alcohol intake, influenza vaccination and contraceptive precautions). c) What action would be taken if a problem related to their Methotrexate occurred. 4) Whether patients would like to be updated with information about Methotrexate and if so how they would like to be updated and what information they would want to be included. <h3>Results</h3> The survey was completed by 100 patients on Methotrexate. The majority of the respondents (58%) were over 61 years and had been taking Methotrexate for longer than a year. Ony 35% of respondents recalled being asked to report shortness of breath and only 42% would report the presence of infection. Forty one per cent of respondents felt a small amount of alcohol was safe. Although all respondents stated that Methotrexate should not be taken in pregnancy, sixty seven percent of respondents did not know whether contraceptive precautions should be taken. Eighty eight percent of respondents would contact the rheumatology adviceline with a problem and 27% of respondents did not know whether it was safe to have the influenza vaccination. Eighty six per cent of respondents would like to be updated with information about Methotrexate with 83% requesting written information on any aspect that would enhance the safe taking of Methotrexate. <h3>Conclusions</h3> The majority of patients taking Methotrexate would not report shortness of breath or the presence of infection, both serious events that would require the Methotrexate to be stopped. It would appear that there is a need to update patients with safely information when they remain on Methotrexate for many years. Patients would welcome being updated with written information to enhance the safe taking of this medication. Further research would be required to identify if providing information at regualr intervals did improve the reporting of side effects and the safe administration of Methotrexate. <h3>Disclosure of Interest</h3> None declared